Application and Results of Different Chemotherapy Regimens in Primary Liver Malignancies

  • G. Falkson
  • B. J. Coetzer
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 100)

Abstract

The approach to treatment of patients with primary liver cancer has differed in different parts of the world. Where the difference in treatment approach is based on true pathological differences in the disease this is justified.

Keywords

Hepatocellular Carcinoma Median Survival Time Eastern Cooperative Oncology Group Primary Liver Cancer Southwest Oncology Group Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baker LH, Saiki JH, Jones SE, Hewlett JS, Brownlee RW, Stephens RL, Vaitkevicius VK (1977) Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group Study. Cancer Treat Rep 61: 1595–1597PubMedGoogle Scholar
  2. 2.
    Berman C (1951) A study of incidence, clinical manifestations, pathology and aetiology in primary carcinoma of the liver. Lewis, LondonGoogle Scholar
  3. 3.
    Bukowski RM, Legha S, Saiki J, Eyre HJ, O’Brein R (1982) Phase II trial of m-amsa in hepatocellular carcinoma–a Southwest Oncology Group Study. Cancer Treat Rep 66 (8): 1651–1652PubMedGoogle Scholar
  4. 4.
    Cavalli F, Rosenzweig M, Renard J, Goldhirsch A, Hansen HH (1981) Phase II study of oral VP-16–213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079–1082PubMedCrossRefGoogle Scholar
  5. 5.
    Cheng E, Lightdale C, Young C, Yagoda A, Fortner J, Golbey R (1983) Phase II trial of (mAMSA) 4’-9-(acridinylamino)methanesulfon-m-anisidide in primary liver cancer. Am J Clin On-col 6: 211–213Google Scholar
  6. 6.
    Chlebowski RT, Chan KK, Tong MJ, Weiner JM, Ryden VMJ, Bateman JR (1981) Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma. Cancer 48: 1088–1095PubMedCrossRefGoogle Scholar
  7. 7.
    Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1982) Full dose adriamycin in hepatocellular carcinoma: clinical and pharmacokinetic results. Proc AACR 23: 110Google Scholar
  8. 8.
    Cochrane AMG, Murray-Lyon IM, Brinkley DM, Williams R (1977) Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 40: 609PubMedCrossRefGoogle Scholar
  9. 9.
    Deutsch HF, Tsukada Y, Sasaki T, Hirai H (1982) The in vivo cytotoxic effects of daunomycinfatty acid complexes on rat hepatomas. Cancer Res (in press)Google Scholar
  10. 10.
    Evans AE, Land VJ, Newton WA, Randolph JG, Sather HN, Tefft M (1982) Combination chemotherapy (vincristine, Adriamycin, cyclophosphamide and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer 50: 821–826PubMedCrossRefGoogle Scholar
  11. 11.
    Falkson G (1959) Chemotherapie van Priroêre Lewerkarsinoom. Spekulum 3: 5–11Google Scholar
  12. 12.
    Falkson G (1975) Therapeutic approaches to hepatoma. Cancer Treat Rev 2: 73–76PubMedCrossRefGoogle Scholar
  13. 13.
    Falkson G (1976) The treatment of liver cell cancer. In: Cameron HM, Lirisell DA, Warwick GP (eds) liver cell cancer. Elsevier, AmsterdamGoogle Scholar
  14. 14.
    Falkson G (1982) The management of tumours of the liver and biliary tract. In: Carter SK, Glatstein E, Livingston RB (eds) Principles of cancer treatment. McGraw-Hill, New YorkGoogle Scholar
  15. 15.
    Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer. Cancer 42: 2149–2156PubMedCrossRefGoogle Scholar
  16. 16.
    Falkson G, Von Hoff D, Klaassen D, Du Plessis H, Van der Merwe CF, Van der Merwe AM, Carbone PP (1980) A phase II study of Neocarzinostatin (NSC 157365) in malignant hepatoma. Cancer Chemother Pharmacol 4: 33–36PubMedCrossRefGoogle Scholar
  17. 17.
    Falkson G, Coetzer B, Klaassen DJ (1981) A phase II study of m-amsa in patients with primary liver cancer. Cancer Chemother Pharmacol 6: 127–129PubMedGoogle Scholar
  18. 18.
    Falkson G, Moertel CC, Maclntyre JM, Lavin P, Engstrom PF, Carbone PP (1981) The value of cytostatic agents in the treatment of patients with primary liver cancer. In: Friedman M, Ogawa M, Kisner D (eds) Diagnosis and treatment of upper gastrointestinal tumors. Excerpta Medica, Amsterdam, pp 455–459Google Scholar
  19. 19.
    Falkson G, McIntyre J, Coetzer B, Schutt AJ, Engstrom PF, Carbone PP (1983) Phase II-III trial of neocarzinostatin versus m-amsa or Adriamycin in hepatocellular carcinoma. Proc AACR 24: 139Google Scholar
  20. 20.
    Falkson G, McIntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer: an ECOG therapeutical trial. Cancer 54 (6): 970–977PubMedCrossRefGoogle Scholar
  21. 21.
    Friedman MA, Demanes JD, Hoffman PG (1982) Hepatomas: hormone receptors and therapy. Am J Med 73: 362–366PubMedCrossRefGoogle Scholar
  22. 22.
    Geddes EW, Falkson G (1970) Malignant hepatoma in the Bantu. Cancer 25: 1271–1278PubMedCrossRefGoogle Scholar
  23. 23.
    Gillman T, Hathorn M, Lamont NME (1957) Alloxan as a possible therapeutic agent for primary carcinoma of the liver. Lancet 272 (6970): 687–688CrossRefGoogle Scholar
  24. 24.
    Ihde DC, Kane RC, Cohen MH, McIntyre KR, Minna JD (1977) Adriamycin therapy in american patients with hepatocellular carcinoma. Cancer Treat Rep 61: 1385–1387PubMedGoogle Scholar
  25. 25.
    Lee Yeu Tsu M (1977) Systemic and regional treatment of primary carcinoma of the liver. Cancer Treat Rev 4: 195–212CrossRefGoogle Scholar
  26. 26.
    Leichman L, MacDonald B, Dindogin A, Samson M (1982) Platinum: a clinically active drug in advanced adenocarcinoma of the stomach. Proc AACR 23: 110Google Scholar
  27. 27.
    Melia WM, Westaby D, Williams R (1981) Diaminodichloride–platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 7: 275–280PubMedGoogle Scholar
  28. 28.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP-16 and Adriamycin. Cancer 51: 206–210PubMedCrossRefGoogle Scholar
  29. 29.
    Morstyn G, Ihde DC, Eddy JL, Bunn PA, Cohen MH, Minna JD (1982) Combination chemotherapy with doxorubicin and streptozotocin (DXC/STZ) in hepatocellular carcinoma ( HC ). Proc AACR 23: 113Google Scholar
  30. 30.
    Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with Adriamycin: preliminary communication. Cancer 36: 1250–1257PubMedCrossRefGoogle Scholar
  31. 31.
    Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46: 2717–2722PubMedCrossRefGoogle Scholar
  32. 32.
    Stein SH, Ajani JA, Karlin DA, Nelson RS (1983) Combination chemotherapy of hepatocellular carcinoma with 5-fluorouracil, Adriamycin, mitomycin-C and methyl-CCNU ( FAMMe ). Proc ASCO 2: 120Google Scholar
  33. 33.
    Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL (1977) A phase II study of Adriamycin (NSC 123 127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39: 1923–1929PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1986

Authors and Affiliations

  • G. Falkson
    • 1
  • B. J. Coetzer
    • 1
  1. 1.Department of Cancer ChemotherapyUniversity of PretoriaPretoriaRepublic of South Africa

Personalised recommendations